Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn’t Even Hit Yet
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) reported Q4 2025 revenue of $12.5 billion, essentially flat year-over-year, with full-year 2025 revenue reaching $48.2 billion. The pharmaceutical giant delivered non-GAAP EPS of $1.26 for the quarter, which included a $(0.60) impact from Orbital Therapeutics acquisition charges. The company announced results on Thursday, February 5, 2026, before market open.
Growth Portfolio Drives Performance
Bristol Myers’ Growth Portfolio surged 16% to $7.4 billion in Q4, demonstrating the company’s successful product diversification strategy. Key contributors included Opdivo at $2.69 billion (+9%), Eliquis at $3.45 billion (+8%), and standout performers Breyanzi at $392 million (+49%) and Camzyos at $353 million (+59%).
However, the Legacy Portfolio declined 15% to $5.1 billion as generic competition intensified. Revlimid plummeted 55%, while Sprycel dropped 60%, reflecting the patent cliff challenges facing the company.
Full-Year Results and Outlook
For full-year 2025, Bristol Myers achieved non-GAAP EPS of $6.15, a substantial improvement from prior year levels, with net income of $7.1 billion and gross profit of $34.3 billion.
The company provided 2026 guidance projecting revenue of $46.0 to $47.5 billion, representing a 3% decline at midpoint due to continued legacy portfolio erosion. Management expects non-GAAP EPS of $6.05 to $6.35 with gross margins of 69% to 70%.
CEO Boerner stated the company has “strong momentum in Growth Portfolio, potential for industry-leading sustainable growth into 2030s, data-rich 2026 with multiple pivotal readouts.”
Capital Allocation and Pipeline
Bristol Myers increased its quarterly dividend to $0.63, marking the 17th consecutive annual increase. The company achieved its $10 billion debt paydown ahead of schedule and maintains a $5 billion share repurchase authorization.
Pipeline highlights include Camzyos’ positive Phase 3 results in adolescent HCM, Opdivo’s priority review for treatment of adult and pediatric patients with classical Hodgkin lymphoma, and the launch of Cobenfy in neuroscience. The stock gained 7.7% over the past week and trades near $58.40.
Contact [email protected] for any questions or corrections.







